Carlo Colombo - Xbrane Biopharma Head of Production Controlled Release Generics
| XBRANE Stock | SEK 0.36 0.01 2.70% |
Executive
Dr. Carlo Colombo no longer serves as Head of Production Controlled Release Generics of Xbrane Biopharma AB effective as of February 28, 2018. He has held the position since 2015. He holds a Ph.D. degree in Industrial Chemistry from the University of Milano. He has more than 15 years of experience from pharmaceutical manufacturing from API manufacturers ICI and Euticals. He has held positions as site director for 5 different API production plants across Euticals and ICI, latest as site director for ICI Cellole plant. He has ample experience from all aspects of pharmaceutical manufacturing including regulatory requirements, process and supply chain optimization and quality control. He is also Member of the Board and Partner of Exorao Life Science S.r.l. and Italien Food Club S.r.l.
| Age | 41 |
| Professional Marks | Ph.D |
| Phone | 46 7 60 34 67 33 |
| Web | https://www.xbrane.com |
Xbrane Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1313) % which means that it has lost $0.1313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3703) %, meaning that it generated substantial loss on money invested by shareholders. Xbrane Biopharma's management efficiency ratios could be used to measure how well Xbrane Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 |
Xbrane Biopharma Leadership Team
Elected by the shareholders, the Xbrane Biopharma's board of directors comprises two types of representatives: Xbrane Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xbrane. The board's role is to monitor Xbrane Biopharma's management team and ensure that shareholders' interests are well served. Xbrane Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xbrane Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Edman, Director | ||
| Nina Ivers, Head HR | ||
| Maria Edebrink, Head Assurance | ||
| Martin mark, Chief Officer | ||
| David Vikstrm, Chief Officer | ||
| Paolo Sarmientos, Head of Controlled Release Generics | ||
| Associate Gier, CoFounder | ||
| Martin Amark, CEO | ||
| Maris Hartmanis, Director | ||
| David Vikstrom, CTO | ||
| Carlo Colombo, Head of Production Controlled Release Generics | ||
| Anders Tullgren, Chairman of the Board | ||
| Ivan CohenTangui, Director | ||
| Saeid Esmaeilzadeh, Chairman of the Board | ||
| Siavash Bashiri, COO, Head of Biosimilars | ||
| Dina Jurman, Head of Clinical Affairs | ||
| Eva Nilsagard, Director | ||
| Anette Lindqvist, CFO Relations | ||
| Susanna Helgesen, CFO, Head of Investor Relations | ||
| Karin Wingstrand, Director | ||
| Alessandro Sidoli, Director | ||
| Giorgio Chirivi, Director | ||
| Samuel Wagner, CoFounder Board | ||
| Erik Domines, G Counsel |
Xbrane Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xbrane Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Shares Owned By Insiders | 35.23 % | |||
| Shares Owned By Institutions | 22.09 % | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Xbrane Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Xbrane Biopharma's short interest history, or implied volatility extrapolated from Xbrane Biopharma options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xbrane Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |